Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for REGN
-9.52 (-2.61%)
After Hours: 355.83 0.00 (0.00%)
Oct 28, 4:25PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 348.49 - 364.12
52 week 329.09 - 592.59
Open 363.58
Vol / Avg. 1.06M/648,016.00
Mkt cap 37.70B
P/E 55.54
Div/yield     -
EPS 6.41
Shares 103.38M
Beta 1.31
Inst. own 71%
Nov 4, 2016
Q3 2016 Regeneron Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Nov 4, 2016
Q3 2016 Regeneron Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Oct 1, 2016
Sanofi SA and Regeneron Pharmaceuticals Inc IR Thematic Conference Call on Dupilumab at EADV Congress - Webcast
Sep 14, 2016
Regeneron Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference
Sep 12, 2016
Regeneron Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference
Sep 7, 2016
Regeneron Pharmaceuticals Inc at Credit Suisse Antibody Day
Aug 11, 2016
Regeneron Pharmaceuticals Inc at Canaccord Genuity Growth Conference - Webcast
Aug 4, 2016
Q2 2016 Regeneron Pharmaceuticals Inc Earnings Release
Aug 4, 2016
Q2 2016 Regeneron Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 16.18% 15.50%
Operating margin 24.05% 30.05%
EBITD margin - 32.33%
Return on average assets 13.00% 13.47%
Return on average equity 20.07% 20.50%
Employees 4,300 -
CDP Score - 59 E


777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 85
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 51
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Executive Vice President - Research and Development
Age: 58
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Daniel P. Van Plew Senior Vice President, General Manager - Industrial Operations and Product Supply
Age: 42
Bio & Compensation  - Reuters
Michael Aberman M.D. Senior Vice President - Strategy and Investor Relation
Age: 44
Bio & Compensation  - Reuters
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 58
Bio & Compensation  - Reuters
Robert J. Terifay Senior Vice President - Commercial
Age: 55
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. Chief Scientific Officer and President - Regeneron Laboratories, Director
Age: 55
Bio & Compensation  - Reuters